Degarelix
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Degarelix |
| DrugBank ID | DB06699 |
| Brand Names (EU) | Firmagon |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.99% |
Approved Indication (EMA)
FIRMAGON is a gonadotrophin releasing hormone (GnRH) antagonist indicated: - for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | hypertrichosis (disease) | 99.99% | DL |
| 2 | Ambras type hypertrichosis universalis congenita | 99.98% | DL |
| 3 | syndrome with a Dandy-Walker malformation as major feature | 99.98% | DL |
| 4 | malformation syndrome with odontal and/or periodontal component | 99.98% | DL |
| 5 | isolated genetic hair shaft abnormality | 99.98% | DL |
| 6 | allergic urticaria | 99.97% | DL |
| 7 | cold urticaria | 99.86% | DL |
| 8 | familial male-limited precocious puberty | 99.84% | DL |
| 9 | centra precocious puberty 1 | 99.67% | DL |
| 10 | familial isolated trichomegaly | 99.65% | DL |
| 11 | precocious puberty | 99.63% | DL |
| 12 | Plasmodium falciparum malaria | 99.52% | DL |
| 13 | nephrogenic syndrome of inappropriate antidiuresis | 99.48% | DL |
| 14 | aromatase excess syndrome | 99.47% | DL |
| 15 | IgE responsiveness, atopic | 99.29% | DL |
| 16 | recalcitrant atopic dermatitis | 99.12% | DL |
| 17 | subarachnoid hemorrhage (disease) | 99.09% | DL |
| 18 | renal-hepatic-pancreatic dysplasia | 99.04% | DL |
| 19 | thoracic malformation | 98.98% | DL |
| 20 | adult familial nephronophthisis-spastic quadriparesia syndrome | 98.98% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.